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Abstract
Background: Recently, a new subset of CD4
+T helper(Th) cell that predominantly secret cytokine interleukin-9(IL-9)
is identified, termed Th9 cell. It has been reported to participate in tissue inflammation and autoimmune
responses, and induce disease which differed from Th17 cells. Th17 cells have been shown to play a critical role in
viral myocarditis (VMC), but whether Th9 cells are involved in the pathogenesis of VMC remains unclear.
Results: BALB/c mice were intraperitoneally (i.p) injected with coxsackie virus B3(CVB3) for establishing VMC
models. Control mice were treated with phosphate-buffered saline i.p. On day 0,7,14,21,28,35,42 after injection,
myocardial histopathological changes were evaluated by hematoxylin-eosin staining. Splenic Th17 and Th9 cells
subsets were analyzed by flow cytometry. And cardiac IL-17, IL-9 mRNA were measured by semi-quantitative
reverse transcription-PCR and nested PCR, respectively. Results showed the levels of Th17 cells and IL-17 mRNA
obviously increased in VMC mice on 7 day after infection, peaked on day 28, and highly persisted to at least day
42 (p < 0.05). While the frequencies of Th9 cells and IL-9 mRNA showed no significant difference between VMC
and control group throughout the course of the experiment(p > 0.05).
Conclusions: It was differentiated Th17 but not Th9 cells significantly elevated in the development of CVB3-
induced VMC. The microenvironment of VMC seemed to contribute to the differentiation and proliferation of Th17
rather than Th9 cells. Our preliminary data implied Th9 cells could not protect against VMC nor promote the
disease.
Background
Viral myocarditis(VMC) is an important cause of heart
failure in young adults and often progresses to chronic
myocarditis, dilated cardiomyopathy(DCM) requiring
heart transplantation[1]. CVB3, an enterovirus of Picor-
naviridae family, is believed to be the primary pathogen
in human VMC[1,2]. Multiple studies had established
that intraperitoneal inoculation of BALB/c mice with
heart-passaged CVB3 (Nancy strain), can induce inflam-
matory heart disease which closely resembled human
VMC[3], and thus this model has been widely used for
investigating VMC. Previous experiments had indicated
the major mechanisms in the pathogenesis of VMC
were inflammation and autoimmune responses triggered
by the viral infection and mediated by T cells[4,5].
Besides Th1,Th2 and Treg cells, our previous report and
other researches demonstrated Th17 cells which prefer-
entially secret cytokine IL-17 might play an important
role in mediating inflammation of VMC[6-9]. But the
fundamental mechanisms responsible for VMC are not
completely clarified.
Recently, a novel independent Th-cell subset, “Th9”
cells had been recognized[10,11]. Driven by the com-
bined effects of TGF-b and IL-4, it produces large quan-
tities of IL-9 which has long been thought to be a Th2
cytokine. Beside IL-10, Th9 cells secret small amounts
of other Th2-related cytokines such as IL-4, IL-5 and
IL-13. Although the mechanism for the differentiation
and proliferation of Th9 cells have not been fully eluci-
dated, the specific transcription factor PU.1 and inter-
feron-regulatory factor 4 strongly support the existence
and functional relevance of Th9 cells in vivo[12,13].
Developing literature has demonstrated that Th9 cells
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mental autoimmune encephalomyelitis (EAE) and aller-
gic disease[11-17]. Especially, a recent study indicated
that IL-9 involved in antiviral immunity, regulating T
and B cell responses to respiratory syncytial virus
infection in BALB/c mice[18]. It seems Th9 cells pro-
vide a unique contribution to tissue inflammation and
immune responses, and participate in Th17-mediated
diseases. Additionally, Anneli Jäger and colleagues
reported Th17 and Th9 effector cells induced EAE, an
animal model of human multiple sclerosis, with differ-
ent pathological phenotypes, indicated distinct effector
function of Th17 and Th9 cells[14]. Th17 cells had
been shown to be associated to inflammation of
CVB3-induced mice VMC, whether the unique IL-9
producing cells, Th9 participate in development of
VMC and whether the expression level of Th17 differ
from Th9 cells remain to be determined. In this study,
we compared the Th9 and Th17 functions on different
level including cell frequencies and major cytokine
secretion to preliminarily explore whether Th9 cells
involved in the pathogenesis of CVB3-induced mice
VMC, and whether Th9 and Th17 cells differentially
expressed in VMC.
Methods
Animals
Specific pathogen-free male BALB/c mice(6 weeks of
age) were obtained from Shanghai Laboratory Animal
Center, Chinese Academy of Sciences, Shanghai, China
(Certificate No.0062353 -SCXK (SH) 2007-0005). All
animals were housed under pathogen-free conditions at
the Experimental Animal Center of the Guangxi Medical
University. All experiments using mice were performed
in accordance with protocols approved by Guangxi
Medical University Animal Ethics Committee.
Interventions and groups
Heart-passaged CVB3 (Nancy strain, from Institute of
immunology of Guangxi Medical University) was main-
tained by passage through Hep-2 cells. 50% tissue cul-
ture infectious dose (TCID50) assay of Hep-2 cell was 1
×1 0
-7. The CVB3 was diluted in PBS (Solarbio Science
& Technology Co, Ltd, Beijing, China). A total of 105
mice were randomly divided into VMC(n = 70,10 mice/
subgroup) and control groups (n = 35,5 mice/subgroup).
Each group was divided into 7 subgroups (Day0, Day7,
Day14,Day21,Day28,Day35,Day42). The VMC group was
treated with (i.p.) 0.1 ml PBS containing approximately
100TCID50 of the virus. Mice injected (i.p.) with 0.1 ml
PBS were taken as control. The day of injection was
defined as day 0. Surviving mice of 7 subgroups were
separately sacrificed by cervical dislocation on 7 differ-
ent time points, which were day 0,7,14,21,28,35,42 after
injection. Hearts and spleens were removed aseptically
as fresh specimens to be measured.
Histopathological examination
The hearts were fixed in 10% formalin, then embedded
in paraffin. After sectioned along the entire length of
the heart into 5-μm sections, and stained with H&E
(hematoxylin and eosin), histopathological change was
observed by using light microscopy(Nikon Eclipse E800
Microscope, Kawasaki, Kanagawa, Japan). Pathological
scores were graded by two independent researchers in a
blinded manner according to the following scoring sys-
tem: 0, no inflammatory infiltrates; 1, small foci of
inflammatory cells between myocytes or inflammatory
cells surrounding individual myocytes; 2, larger foci of
100 inflammatory cells or involving at least 30 myocytes;
3, 10% of a myocardial cross-section involved; 4, 30% of
a myocardial cross-section involved[19].
Flow cytometric analysis of Th17 and Th9 cells
Splenic cells were gently dispersed through nylon mesh
into a single-cell suspension, washed with RPMI 1640
(Gibco, USA). Lymphocytes were obtained by density
gradient centrifugation from cells with Ficoll Paque
(Solarbio Science &Technology). These cells were sus-
pended in RPMI 1640 medium with 10% FCS (Gibco,
USA) and transferred to each well of 24-well plates.
Cultures were stimulated with phorbol myristate acetate
( P M A ,2 5n g / m l ,S i g m a - A l d r i c h ,U S A )a n di o n o m y c i n
(1 μg/ml, Sigma-Aldrich) in the presence of GolgiPlug
(10
61 ul/cells, BD Biosciences) at 37°C under a 5% CO2
environment. After 4 h of incubation, cells were har-
vested and washed once with PBS. Then cells were incu-
bated with phycoerythrin Cye-5-conjugated anti-mouse
CD4 (PE-Cye-CD4, BD Biosciences). After washed with
PBS, cells were fixed in 4% paraformaldehyde, permeabi-
lized with 0.1% saponin. Then cells were stained with
phycoerythrin-conjugated anti-mouse IL-17 and Alexa
Fluor
® 647 anti-mouse IL-9, and analyzed on a FACS-
Calibur flow cytometer (BD Bioscience). CellQuest soft-
ware (BD Biosciences) was used for data acquisition.
Polymerase chain reaction(PCR) of IL-17 and IL-9 mRNA
Total RNA of heart tissues was extracted using TRIZOL
Reagent
® (Invitrogen, USA), and then converted into
cDNA using an Reverse Transcription kit (Ferma, USA)
according to the manufacturer’s protocol. The primers
for IL-17A, IL-9 and the housekeeping gene b-actin
were designed by Primer Premier 5.0 (Table 1). For IL-
17A amplification semi-quantitative reverse transcrip-
tion-PCR was performed under the following conditions:
pre-heating at 94°C for 3 min, denaturing at 94°C for 30
second(s), annealing at 64.9°C for 30 s, and extension at
72°C for 60 s. The reaction repeated for 35 cycles
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were separated using 2% agarose gel electrophoresis and
visualized by 0.5 mg/ml ethidium bromide staining and
ultraviolet transillumination. The resulting bands (349
b p )w e r em e a s u r e du s i n gt h eD i g i t a lG e lI m a g i n gA n a -
lyst (Nikon 990-Doc 1000, USA). Background density
was subtracted from each band and the relative IL-17
mRNA expressions were normalized to the level of b-
actin transcripts. For IL-9, reverse transcription-PCR
s h o w ni t sm R N Aw a su n d e t e c t a b l ei nh e a r t .T h e nw e
amplified with nested PCR which contains the first and
second round PCR reaction(PCR1 and PCR2). Specific
primers were used for PCR1 reaction. After 3 min at 72°
C, 40 amplification cycles were used (94°C for 45 s, 56°C
for 45 s, and 72°C for 1 min), then 72°C for 6 min. PCR1
products and specific primers were used for PCR2. The
polymerase was activated by incubation at 95°C for 3 min
prior to 40 amplification cycles (94°C for 30 s, 58°C for
30 s, and 72°C for 30 s), followed by 3 min at 72°C. After
PCR2 products were separated by electrophoresis, the
purpose gene were investigated in all samples. IL-9 fre-
quency was determined via direct counting. The presence
of 140 bp band indicated the expression of IL-9mRNA,
while its absence confirmed no expression. Sterile water
was also amplified with nested PCR as the negative con-
trols. Products were sequenced by Sangon Biological
Engineering Technology & Services Co., Ltd., (Shanghai,
China), and blasted in the NCBI Blast bank. All samples
were measured in triplicate.
Statistical analysis
Quantitative variables were expressed as mean±standard
deviation (SD). One-way ANOVA was used for compar-
ison among groups. Qualitative variables of IL-9 mRNA
measured by nested-PCR were expressed as percentages,
and differences in IL-9 mRNA distribution among
groups were obtained using the Chi-Square Tests. Statis-
tical analyses were performed with the use of SPSS 13.0,
p < 0.05 was considered statistically significant.
Results
Development of VMC
Signs of VMC were apparent in the experimental group
after virus injection, including weakness, coat ruffling,
irritability, back arching, lethargy, anorexia, weight loss,
and some mice died. Number of surviving mice in VMC
subgroups from day 0 to 42 were: 10, 9, 7, 6, 6, 7 and 7,
respectively. The cardiac pathological scores of VMC
significantly increased on day 7 (1.8 ± 0.5), peaked on
day 14 (2.8 ± 0.4). Then the severity of inflammation
gradually ameliorated. In contrast, the control group
showed no inflammatory cell infiltration, necrosis or
fibrosis lesions in hearts, and no mice died(Figure 1).
Distinct frequencies of Th17 and Th9 cells
A ss h o w ni nF i g u r e2 ,f r e q u e n c i e so fs p l e n i cT h 1 7c e l l s
(CD4
+IL17
+/CD4
+Tc e l l s )i nV M Cg r o u pf r o md a y0t o
42 were: 0.76 ± 0.34%,2.32 ± 0.78%, 2.70 ± 0.86%, 2.72
± 0.72%, 4.99 ± 0.85%, 2.94 ± 0.48%,2.24 ± 0.42%. Th17
cells in the control group from day 0 to 42 were 0.87 ±
0.45%, 0.93 ± 0.14%, 0.82 ± 0.09%, 0.97 ± 0.43%, 0.98 ±
0.42%, 0.96 ± 0.54%, 1.02 ± 0.63%. These data indicated
the time-course of Th17 cells were significant higher
than control group from day 7, and peaked on day 28,
then wanning(p < 0.05). Frequencies of Th9 cells (CD4
+IL9
+/CD4
+Tc e l l s )i nV M Cg r o u pf r o md a y0t o4 2
were: 0.62 ± 0.17%, 0.58 ± 0.21%, 0.61 ± 0.24%, 0.67 ±
0.28%,0.65 ± 0.25%,0.57 ± 0.28%,0.64 ± 0.26%. Th9 cells
in the control group from day 0 to 42 were 0.53 ±
0.17%, 0.57 ± 0.23%, 0.54 ± 0.27%, 0.58 ± 0.16%, 0.66 ±
0.30%, 0.69 ± 0.32%,0.63 ± 0.27%. Results showed no
significant difference between the VMC and control
group on each time point(all p > 0.05).
Different level of IL-17 and IL-9 mRNA
A ss h o w ni nF i g u r e3 ,f o rc a r d i a cI L - 1 7m R N A ,i t s
intensity normalized to b-actin in VMC group from day
0 to 42 were: 0.27 ± 0.18, 0.73 ± 0.32, 0.87 ± 0.25, 0.89
± 0.34, 1.16 ± 0.24, 0.93 ± 0.28, 0.85 ± 0.27. Data in the
control group from day 0 to 42 were: 0.32 ± 0.11, 0.27
± 0.15, 0.32 ± 0.18, 0.35 ± 0.13, 0.36 ± 0.17, 0.29 ± 0.14,
0.31 ± 0.18. In accordance with flow cytometry analysis
of Th17 cells, IL-17 mRNA obviously upregulated in
mice with VMC from day 7 and peaked on day 28(p <
0.05). For IL-9, the percentages of its cardiac mRNA in
V M Cg r o u pf r o md a y0t o4 2w e r e :6 0 % ,5 5 . 6 % ,7 1 . 4 % ,
66.7%, 66.7%, 71.4%, 57.1%. Results in the control group
were 60%, 40%, 60%, 60%, 60%,60% and 40%. Fisher’s
Exact Test was used to analyze the differences of IL-9
mRNA percentages between the VMC and control
groups because of small size. No significant difference
was observed throughout the course of the experiment
(all p > 0.05), which was in agreement with our observa-
tions on the frequencies of Th9 cells.
Table 1 Sequences of primers for PCR
Molecule Sequence (5’ -3’) Length
IL-17 sense:5’GTCAATGCGGAGGGAAAG 3’ 349 bp
[GenBank:16171] antisense:5’CACGAAGCAGTTTGGGAC 3’
b-actin sense: 5’CCAGCCTTCCTTCTTGGGTAT 3’ 102 bp
[GenBank:11461] antisense: 5’TTGGCATAGAGGTCTTTACGG 3’
IL-9 PCR1 sense: 5’GCATCAGAGACACCAATTACCT
3’
140 bp
[GenBank:16198] PCR1 antisense: 5’
TTAAGGAGGGGAGGTTTTGTA 3’
PCR2 sense:
5’AACTGATGATTGTACCACACCGTGC 3’
PCR2 antisense: 5’
AGGACGGACACGTGATGTTCTTTAG 3’
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Figure 1 The severity of VMC were evaluated by histopathological examination. A. Representative of myocardial histopathologic images in
VMC group(H&E, original magnification × 400). Myocardial was normal on Day 0. A few scattered small foci of myocyte necrosis were observed
on Day 7. The severity of myocardial necrosis and interstitial inflammatory cell infiltration were markedly increased on Day 14. Then the degree
of inflammation gradually decreased. Fibrous hyperplasia was found from Day 28 on. B. The results of statistical analysis for pathological scores in
different groups. n = 5 mice for per control subgroup, n = 6-10 for per VMC subgroup. Values are expressed as mean ± SD. *, p < 0.01 vs.
control subgroups sacrificed on the same time point; #, p < 0.05 vs. other VMC subgroups. VMC, Viral myocarditis.
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Figure 2 The frequencies of Th17 and Th9 cells were investigated by flow cytometry. A. Representative pictures for Th17 cells, and Th9
cells in VMC group. Numbers in upper left quadrants and lower right quadrants indicate the separate percentages of CD4
+IL-17
+IL-9
- Th17 cells
and CD4
+IL-9
+IL-17
- Th9 cells, respectively. B,C. The results of statistical analysis for the alteration of Th17 and Th9 cells in different groups. n = 5
mice for per control subgroup, n = 6-10 for per VMC subgroup. Values are expressed as mean ± SD. *, p < 0.05 vs. control subgroups sacrificed
on the same time point; #, p < 0.01 vs. other VMC subgroups; Δ, p < 0.01 vs. Day14,21,28,35,42 subgroups of VMC.
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The results of our experiment showed that the extent of
myocardial inflammatory infiltrations peaked around day
14 after injection with CVB3. It was differentiated Th17
cell and its major cytokine IL-17 dramatically increased
in VMC from day 7 post-infection, and persisted at least
to day 42. But for Th9 cells frequencies, there was no
obvious difference between VMC and control group
throughout the course of the experiment. The similar
phenomena also appeared on the level of IL-9 mRNA.
In agreement with low frequencies of Th9 cells in
spleens, we found cardiac IL-9 mRNA was undetectable
by semi-quantitative reverse transcription PCR. Then we
performed a more sensitive method for original speci-
mens, nested PCR[20]. These manifestations suggested
the Th9 cells in CVB3 and PBS treated BALB/c mice
might be very low.
Several recent discoveries of Th9 cells found in mice and
human have broadened our understanding of autoimmune
disease, because this unique IL-9-producing subset seems
can explain some phenomena underlying T cell-mediated
tissue inflammation and antiviral immunities[21]. Th9
cells might contribute to immunity against EAE, colitis
and peripheral neuritis, allergic inflammation, allergic rhi-
nitis and Alzheimer’s disease[11-17,22-24]. On the other
hand, emerging literature identified IL-9 involved in anti-
inflammatory, antiviral, nephroprotective activity, and
enhanced the immunosuppressive function of Tregs
[18,25,26]. These conflicting observations suggested Th9
cells can exert pro-inflammatory or anti-inflammatory
activities, and might function as both a positive and nega-
tive regulator of immune response depending on the con-
text. It is therefore possible that Th9 cells can protect
against VMC or promote the disease, and may be differen-
tially affected in mice with VMC or not, hence the present
study was undertaken. Contrary to our hypothesis, our evi-
dence clearly showed no significant difference of Th9 cells
and IL-9 mRNA throughout the development of the
VMC. Data in cell frequencies and major related cytokine
secretion levels failed to demonstrate Th9 cells could be
differentially regulated in mice with VMC or not. There
are at least two possible explanations for our observation.
Firstly, as we known, IL-9 promoted the survival and acti-
vation of various cellular targets, including mast cells, B
cells, T cells, and structural cells[27,28]. IL-9
+CD4
+ cells
were detected in all groups. So we hypothesis that Th9
cells might relate to both maintenance of cardic health
and heart tissue destruction by CVB3. Secondly, although
there are multiple cell types responsive to IL-9, and the
biological effects of IL-9 are pleiotropic[29]. Many scholars
believed that IL-9 was not obligatory for pathogenesis of
some diseases and other cytokines can compensate its
effect. For example, IL-9 had been shown to participate in
the defense against helminth infections, asthma and
allergy[17,30]. But some experiments demonstrated that
IL-9 was not required for the expulsion of the intestinal
p a r a s i t i cn e m a t o d eN i p p o s t rongylus brasiliensis, the
chronic allergen challenge induced bronchial mast cell
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Figure 3 The levels of cardiac IL-17 and IL-9 mRNA were detected by PCR.A .R e p r e s e n t a t i v ei m a g e ss h o w i n gs e m i - q u a n t i t a t i v er e v e r s e
transcription-PCR products for IL-17 mRNA transcription in VMC group. Lane M, 50-bp marker ladder;Lanes1-7, Day 0,7,14,21,28,35,42 subgroups.
B.Collective analyses of results from all groups for IL-17 mRNA. The products were normalized versus b-actin mRNA band intensities. C. The
percentages of cardiac IL-9 mRNA were detected by nested-PCR. Representative images showing PCR products of the samples. Lane M,100-bp
marker ladder;Lanes1,2, samples of control group; Lanes 3-16, samples of different time point in VMC groups; Lanes 3,4, Day0; Lanes 5,6, Day7;
Lanes 7,8, Day14; Lanes9,10, Day21; Lanes11,12, Day28; Lanes13,14, Day35; Lanes 15,16, Day42. Lane17, sterile water were amplified as the
negative control. n = 5 mice for per control subgroup, n = 6-10 for per VMC subgroup. Values are expressed as mean ± SD. *, p < 0.01 vs.
control subgroups sacrificed on the same point time; #, p < 0.05 vs. other VMC subgroups;Δ, p < 0.01 vs. Day14,21,28,35,42 subgroups of the
VMC group.
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monary inflammation or airway hyperreactivity[31-33]. In
our current experiment, no change of Th9 cells had been
observed in VMC. From this point of view, we can’t
exclude the possibility that the pathogenic process of
VMC is not associated with Th9 cells. Further investiga-
tion will be of particular interest to determine whether
neutralize Th9 cytokines and/or in IL-9 mutant mice espe-
cially in IL-9/IL-9R-deficient mice model, lead to different
viral immunity in the CBV3-induced VMC.
Th17 cells have been identified as a unique CD4
+ Th
subset, which is characterized by production of pro-
inflammatary cytokine IL-17[34]. Th17 subset has
sparked great interest in the role of a broad range of
immune-mediated tissue injury, including organ-specific
autoimmunity in heart, VMC. Existing knowledge
related to Th17 cells in VMC suggest that Th17 cells
contribute to viral replication, facilitate the humoral
immune response in acute VMC, and anti-IL-17 anti-
body can markedly reduce mice VMC severity[6-9]. Our
experiment found Th17 cells highly expressed in the
pathogenesis of VMC, which enriched from day 7,
peaked on day 28, persisted at least to day 42 post-infec-
tion. But the change of Th9 cells did not reach statisti-
cal significance. It seems the microenvironments of
VMC contribute to differentiation and proliferation of
Th17 rather than Th9 cells. Meanwhile, although inves-
tigations in vitro had presented a complex regulatory
network between Th17 and Th9 cells, and IL-9 could
function as an autocrine growth factor that facilitates
the expansion of Th17 cells populations[14,16,25,35,36].
It seems high expression of Th17 have no effect on Th9
cells in VMC. The exact relationship between Th17 and
Th9 cells need future in vitro experiment to clarify.
There are several limitations in our study. Firstly,
although the Th9 is the major CD4
+T cell subset excit-
ing IL-9, and we separately detected the CD4
+IL-7
+IL-9
-
Ta n dC D 4
+IL-9
+IL-7
- T cells by flow cytometry, the
present study cannot ascertain whether Th17 cells pro-
duced IL-9 in VMC[12,37]. Secondly, we focused on
Th9 cells’major cytokine IL-9, but we did not exten-
sively detect other cytokine such as IL-10, which is
undetectable in human. Furthermore, we did not per-
form study in vitro and isolate Th17/Th9 cells to
explore their relationship.
Conclusion
Our preliminary data disclosed Th17 rather than Th9
cells significantly elevated in the development of CBV3
induced VMC mice, including cell frequencies and
major related cytokine secretion levels. It seems the
microenvironments of mice with VMC affect the differ-
entiation and proliferation of Th17 but not Th9 cells.
Whether Th9 cells participate in the pathogenesis of
VMC warrants further research. The study of these
manifestations might lead to new insight into the imbal-
ance of Th17/Th9 cells in tissue inflammation and auto-
immune responses, and the Th9 cells hypothesis might
evolve into an even more intricate story.
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